Ultram ER News
Biovail's profits and sales slip in Q2 - Ottawa Business Journal
As well, royalty and other revenues fell by 36.9 per cent to $4.9 million as a result of the completion of a joint promotion between Biovail's Ultram ER ...
UPDATE: Labopharm's FDA Troubles May Not Be All Its Doing - CNNMoney.com
... time for (marketing partner) Purdue to launch prior to potential genericization of the once-daily tramadol market by the Ultram ER generic," Gowd wrote. ...
UPDATE: Labopharm's FDA Troubles May Not Be All Its Doing - CNNMoney.com
... time for (marketing partner) Purdue to launch prior to potential genericization of the once-daily tramadol market by the Ultram ER generic," Gowd wrote. ...
Friday's Health Winners & Losers - TheStreet.com
Labopharm competitor Biovail (BVF - Cramer's Take - Stockpickr), which makes painkiller Ultram ER, offered news as well. It restated its 2004, 2005 and 2006 ...
Biovail "neutral," target price raised - newratings.com
... significantly ahead of the estimates and the consensus due to higher-than-expected revenues and an increase in sampling and inventory from Ultram ER. ...
Biovail's Net Income Rose 37 Percent in the First Quarter - Bloomberg
... said earnings rose 37 percent in the first quarter as the company increased sales of the pain drug Ultram ER and the herpes treatment Zovirax. ...
Biovail Q1 Profit Rises 37%; Revenue Up 11%; Backs FY07 Outlook ... - Trading Markets
Other products that contributed to total revenues included Ultram ER with $30 million, up from $15.1 million and Zovirax franchise, which added $37.3 ...
Biovail "neutral," target price raised - newratings.com
... significantly ahead of the estimates and the consensus due to higher-than-expected revenues and an increase in sampling and inventory from Ultram ER. ...
Biovail Reports First-Quarter 2007 Financial Results, Plans to ... - Business Wire (press release)
Our confidence in Ultram® ER is further supported by recent prescription trends, and with an FDA action date for BVF-033 in July and a maturing development ...
Biovail posts 37% jump in Q1 profits on stronger Ultram sales - Ottawa Business Journal
The Toronto-based company's revenues rose by 12 per cent to $238 million, boosted by a 99-per-cent jump in sales of its chronic-pain medication Ultram ER to ...
Ultram ER RSS Feed